利用组织芯片技术观察Hp感染与p53、p63表达在胃癌中的相关性

目的:研究Hp与p53、p63表达与胃癌临床病理特征的关系。方法:应用免疫组化技术检测人胃癌组织芯片144芯中Hp、p53和p63的表达。结果:144例胃癌标本中p53阳性表达80例（55.6%）,p63阳性表达53例（36.8%）,Hp阳性表达94例（65.3%）。p53表达与胃癌组织学分型、病理分级和淋巴结转移有关(P＜0.05),与肿瘤部位及浸润深度无关(P＞0.05);p63在低分化腺癌组织中表达率明显高于高、中分化腺癌(P＜0.05),与肿瘤部位、浸润深度及淋巴结转移无关(P＞0.05);Hp主要寄居在胃窦,且其感染与肿瘤组织学分型和病理分级有关(P＜0.05),与淋巴结转移及浸润深度无关(P＞0.05)。胃癌组织中Hp感染与p53表达呈正相关(r=0.20,P＜0.05)。结论:p53和p63的高表达与胃癌的发生及进展密切相关,但p53和p63在胃腺癌发生发展过程中并无交互作用, Hp感染与p53高表达存在一定相关性。     

应用组织芯片技术联合检测缝隙连接蛋白43与E-钙黏蛋白在膀胱移行细胞癌中的表达及意义

目的探讨缝隙连接蛋白43(Connexin43)和E-钙黏蛋白(E-cadherin)在膀胱移行细胞癌(BTCC)组织中的表达及其临床意义。方法采用免疫组化SP法联合检测65例BTCC组织和15例正常膀胱组织中Connexin43和E-cadherin的表达,并进行两者的相关性分析。结果①在正常膀胱组织中Connexin43和E-cadherin阳性表达主要位于细胞膜,BTCC组织中Connex-in43和E-cadherin阳性表达主要位于细胞质。②Connexin43和E-cadherin蛋白在BTCC中的表达率明显下降,且与BTCC的分级分期密切相关。③Connexin43和E-cadherin蛋白在BTCC中的表达存在明显的相关性(rs=0.617,P<0.005)。结论①BTCC中存在Connexin43和E-cad-herin蛋白表达的下降,且两者之间存在明显的相关性。②Connexin43和E-cadherin表达水平可以作为BTCC分化水平的重要生物学指标,从而用于膀胱癌的预后判断。     

Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer

Summary The role of caveolin 1 (CAV1), a structural component of caveolae in breast cancer is controversial, although most studies suggest that it functions as a tumor-suppressor gene. In addition, some studies have identified CAV1 as a marker of myoepithelial cells. Since myoepithelial markers are frequently expressed in breast carcinomas with a basal-like phenotype, which are frequently occurring tumors in women with BRCA1 germline mutations, we evaluated whether CAV1 was associated with a basal-like phenotype in 509 sporadic and 47 hereditary BRCA1-/BRCA2-associated carcinomas. Immunohistochemistry was performed on tissue microarrays and cases were classified as having a basal-like-phenotype if they were estrogen-receptor- and HER2-negative but cytokeratin 5/6- and/or epidermal growth factor receptor-positive. In sporadic carcinomas, CAV1 expression was found in 21 out of 496 valuable cases (4.2%). A basal-like-phenotype was found in 53 out of 498 (10.6%) cases. A strong association was found between CAV1 expression and a basal-like-phenotype, since 52% of tumors that expressed CAV1 had this phenotype, compared with only 9% of CAV1-negative carcinomas (p<0.001). CAV1 was expressed in six (12.8%) familial cases, five of which had a basal-like-phenotype (p = 0.009). Moreover, these six CAV1-positive cases were BRCA1 tumors. The difference in the frequency of CAV1 expression between BRCA1- and BRCA2-associated tumors was statistically significant (p = 0.024). In conclusion, this study reports for the first time CAV1 expression in BRCA1 and BRCA2 hereditary breast cancer and identifies CAV1 as a marker associated with a basal-like-phenotype in both hereditary and sporadic breast cancer.